OraSure Technologies, Inc. (NASDAQ:OSUR) was downgraded by analysts at Jefferies Group LLC from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, November 2nd, Marketbeat.com reports.
A number of other brokerages have also commented on OSUR. Zacks Investment Research lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Canaccord Genuity restated a “buy” rating and set a $22.00 target price on shares of OraSure Technologies in a report on Tuesday, September 19th. BidaskClub cut OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Finally, Stephens restated an “overweight” rating and set a $19.00 target price (up previously from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $18.21.
Shares of OraSure Technologies (NASDAQ OSUR) traded up $2.59 during trading hours on Thursday, hitting $16.55. The stock had a trading volume of 4,774,388 shares, compared to its average volume of 887,916. OraSure Technologies has a 52 week low of $8.21 and a 52 week high of $23.01. The firm has a market capitalization of $1,000.00, a price-to-earnings ratio of 26.42, a PEG ratio of 2.64 and a beta of 1.39.
OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.09. The company had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The firm’s quarterly revenue was up 31.0% compared to the same quarter last year. During the same period last year, the company posted $0.11 earnings per share. sell-side analysts forecast that OraSure Technologies will post 0.42 EPS for the current fiscal year.
In other news, Director Mara G. Aspinall bought 5,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The shares were purchased at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the purchase, the director now owns 5,000 shares of the company’s stock, valued at approximately $71,150. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brian Smith sold 9,112 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $20.47, for a total value of $186,522.64. Following the completion of the sale, the insider now owns 32,477 shares in the company, valued at approximately $664,804.19. The disclosure for this sale can be found here. Insiders have sold a total of 58,035 shares of company stock worth $1,297,612 in the last quarter. 6.40% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the business. First Mercantile Trust Co. acquired a new position in shares of OraSure Technologies during the 2nd quarter worth approximately $104,000. Pinebridge Investments L.P. acquired a new position in shares of OraSure Technologies during the 2nd quarter worth approximately $131,000. Victory Capital Management Inc. acquired a new position in shares of OraSure Technologies during the 1st quarter worth approximately $100,000. Oppenheimer Asset Management Inc. acquired a new position in shares of OraSure Technologies during the 3rd quarter worth approximately $186,000. Finally, ARP Americas LLC acquired a new position in shares of OraSure Technologies during the 3rd quarter worth approximately $221,000. 94.41% of the stock is currently owned by hedge funds and other institutional investors.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with our FREE daily email newsletter.